Gilead-Teva Patent Deal Cost Drug Buyers Over $2B, Jury Told

By Bonnie Eslinger · June 13, 2023, 10:23 PM EDT

A retired Harvard Medical School health economics professor testified Tuesday in a California federal antitrust trial over claims that Gilead and Teva struck an illegal "pay for delay" patent deal over...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

In re HIV Antitrust Litigation

Case Number

Court

California Northern

Nature of Suit

Anti-Trust

Date Filed

May 14, 2019

Recent Articles By Bonnie

November 05, 2024
Eye-Rolling Must Stop, Judge Warns Before False Ad Trial
October 11, 2024
9th Circ. Backs Planned Parenthood's $14M Atty Fee Win
October 03, 2024
Texas Transgender Health Rule Suit Paused For Gov't Appeal
October 02, 2024
Lab Co. Settles Bogus Testing Claims With Feds For $27M
August 28, 2024
Del. Justices OK Mid-Case Appeal In Zantac Class Suit
August 16, 2024
States Get Teva Generic Price-Fix Case On Docket As 1st Trial
August 09, 2024
DC Circ. Pans Suit Claiming HHS Caused Health Aid Shortage
June 28, 2024
Texas Justices Back Ban On Gender Affirming Care For Minors
June 28, 2024
Jury Convicts Seattle Doctor In NBA Health Fraud Case
May 17, 2024
Pfizer Unit Wins $107.5M Patent Verdict Against AstraZeneca